复牌！002166 拟易主

Core Viewpoint - Rhine Biotech is undergoing a change in control, with Guangzhou Defu Nutrition becoming the new controlling shareholder, effective from December 24, following a series of agreements signed on December 22 [2][3]. Shareholder Changes - The controlling shareholder Qin Benjun will transfer 8.09% of his shares to Guangzhou Defu Nutrition and will relinquish 25.50% of his shares while retaining 3% voting rights [2][4]. - After the transaction, Qin Benjun will hold 28.50% of Rhine Biotech's shares and 4.14% of the voting rights [3][4]. Transaction Details - The total transaction price for the share transfer is 646 million yuan (including tax), with a transfer price of 10.76 yuan per share, representing a premium of 23.68% over the closing price of 8.70 yuan on December 9 [2][4]. Company Background - Guangzhou Defu Nutrition was established on December 2, 2025, by Defu Capital and currently has not engaged in any actual business activities [5]. - Defu Capital focuses on the healthcare and consumer sectors, aiming to leverage its resources to enhance Rhine Biotech's operational efficiency and governance structure [5]. Strategic Expansion - Rhine Biotech plans to expand its industry chain through acquisitions, specifically by purchasing 80% of Beijing Jinkangpu Food Technology Co., Ltd. [6]. - The company aims to create a closed-loop industry chain from raw materials to formulation solutions, enhancing business synergy with Beijing Jinkangpu, a leading supplier of nutritional fortifiers [6][8]. Financial Overview - As of September 30, 2025, Rhine Biotech reported total assets of 4.985 billion yuan and net assets of 3.162 billion yuan, with a net profit of 163 million yuan for 2024 and 70.4 million yuan for the first three quarters of 2025 [8][9]. - Beijing Jinkangpu's total assets were reported at 593 million yuan, with a net profit of 70.3 million yuan for 2024 and 40.3 million yuan for the first three quarters of 2025 [7][8].